Neumora Therapeutics (NMRA) Total Current Liabilities (2022 - 2026)

Neumora Therapeutics' Total Current Liabilities history runs 5 years deep, the most recent figure standing at $30.1 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 6.1% year-over-year to $30.1 million in Q1 2026; TTM through Mar 2026 was $30.1 million, a 6.1% increase from a year earlier, with the FY2025 full-year figure at $32.5 million, up 8.58% from the prior year.
• Total Current Liabilities declined to $30.1 million in Q1 2026 per NMRA's latest filing, from $32.5 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $32.5 million in Q4 2025 and bottomed at $21.2 million in Q2 2025.
• The 5-year median for Total Current Liabilities is $27.1 million (2025), against an average of $27.1 million.
• Across the five-year window, Total Current Liabilities gained 19.02% in 2024 and decreased 18.59% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $23.7 million in 2022, then rose by 5.97% to $25.1 million in 2023, then climbed by 19.02% to $29.9 million in 2024, then climbed by 8.58% to $32.5 million in 2025, then slipped by 7.2% to $30.1 million in 2026.
• Per Business Quant, the three latest NMRA Total Current Liabilities figures stand at $30.1 million (Q1 2026), $32.5 million (Q4 2025), and $25.8 million (Q3 2025).